Abstract
Aims:
Grade heterogeneity is one of the most debated issues in the grading of urothelial carcinomas. The 2022 WHO classification states that approximately one-third of urothelial carcinomas exhibit grade heterogeneity and suggests that the presence of ≥5% high-grade component may justify classification as high-grade. Nevertheless, the need for further evidence was also emphasized. This study aimed to evaluate the prognostic impact of the high-grade component in urothelial carcinomas with grade heterogeneity and to determine a threshold value for high-grade proportion that is clinically meaningful for grading.
Methods:
This retrospective study included 180 cases of non-muscle-invasive urothelial carcinoma with grade heterogeneity, diagnosed between January 2019 and August 2022 on TUR specimens, with available clinical data. Recurrence and survival time were assessed. Cases with >90% high-grade component were excluded.
Results:
Recurrence was observed in 26.7% of cases. The two-year survival rate was 73.3%. While no significant association was found between recurrence and the proportion of high-grade component, survival time significantly decreased as the proportion of high-grade component increased. ROC curve analysis identified 27.5% as the cut-off value associated with adverse prognosis.
Conclusion:
In non-muscle-invasive urothelial carcinomas, the proportion of high-grade component showed a strong association with survival. Together with literature findings, our results suggest that a threshold higher than 5% may be more appropriate for assigning tumors to the high-grade category. Nonetheless, risk stratification incorporating tumor size and extent remains essential for prognostic evaluation.
Highlights
Grade heterogeneity is observed in a substantial proportion of urothelial carcinomas and remains a major source of diagnostic variability.
Higher proportions of high-grade component were associated with shorter survival, with 27.5% identified as a potential prognostic threshold.
A threshold higher than 5% for defining high-grade tumors may improve grading consistency and prognostic accuracy in clinical practice.
Introduction
Histological grading of urothelial carcinomas (UC) is one of the key determinants in guiding treatment protocols. The two-tier grading system was first introduced in the 1998 WHO/ISUP consensus report and was maintained in the 2004 and 2016 WHO classifications []. Most recently, the fifth edition published in 2022 has continued to adopt this two-tier grading system for UC. Studies comparing low- and high-grade UC have shown that this system also correlates with the prevalence of genetic alterations. However, in light of accumulating molecular evidence, some reports suggest that the three-tier grading system, originally used in the 1973 classification, demonstrates a stronger correlation with both clinical outcomes and genetic alterations []. In fact, based on these findings, it has recently been proposed that the three-tier classification may be more appropriate for clinical use []. Building on these observations, a hybrid four-tier system that subdivides the high-grade category into G2 (Grade 2) and G3 (Grade 3) has also been proposed []. One of the main arguments for these proposals is that the three-tier system provides higher interobserver reproducibility compared to the two-tier system.
Among the most debated aspects of histological grading in UC is grade heterogeneity []. Various studies have reported that 5%–30% of non-invasive carcinomas contain both low-grade and high- grade components [, ]. In such cases, deciding which component should determine the final tumor grade is of critical importance. Grade heterogeneity further reduces interobserver reproducibility, a problem compounded by the inherent subjectivity of the histological parameters used to distinguish low-grade from high-grade lesions [].
Although the histological grading system of UC has remained unchanged since the 2004 WHO classification, the prognostic relevance of grade heterogeneity has become an increasingly debated issue in recent years []. According to the 2004 WHO classification, non-invasive urothelial carcinomas with grade heterogeneity were classified in the high-grade category. However, some studies have shown that the prognosis of such tumors may resemble that of low-grade carcinomas rather than high-grade carcinomas [].
The 2022 WHO classification of urinary and male genital tumours specifically highlights intratumoral grade heterogeneity as a problematic area for pathologists, noting that it often results in a higher frequency of high-grade diagnoses []. While molecular studies may eventually provide more definitive insights, it is currently recommended to adopt a standardized approach by considering a defined cut-off proportion of high-grade component []. The 2022 WHO classification states that approximately one-third of UC display grade heterogeneity and suggests that if a low-grade tumor contains ≥5% high-grade component, the tumor should be graded as high-grade. Conversely, tumors with <5% high-grade component should be reported as “low-grade UC with <5% high-grade component.” In addition, all histological subtypes of UC and those with divergent differentiation are classified in the high-grade category [].
In this study, we aimed to investigate the prognostic impact of the high-grade component in UC with intratumoral grade heterogeneity and, based on prognostic data, to determine a threshold value for the high-grade proportion with meaningful implications for grading.
Materials and methods
Transurethral resection of bladder tumor (TURBT) specimens diagnosed between January 2019 and August 2022 were retrieved from the archives of the Ministry of Health Ankara Dışkapı Training and Research Hospital. All hematoxylin and eosin slides were re-evaluated according to the 2022 WHO Classification of Urinary System Tumors. The proportion of low- and high-grade components and the presence of lamina propria invasion were recorded. Cases with >90% high-grade component, without any high-grade component, muscle-invasive tumors, carcinoma in situ, specific histological subtypes, and recurrent carcinomas initially diagnosed before 2019 were excluded.
In total, 184 cases were identified. Survival, recurrence, and progression were evaluated. Progression was defined as an increase of ≥5% in the high-grade component or the presence of muscle invasion in follow-up specimens (re-TUR or cystectomy). Four cases were excluded due to missing clinical data, leaving 180 for analysis. Recurrence-negative status required a minimum follow-up of 2 years.
Demographic and clinical data (age, sex, survival, recurrence) were obtained from the hospital’s electronic database. Statistical analyses were performed using SPSS version 27.0 (IBM Corp., Armonk, NY, USA). Continuous variables were summarized as mean ± standard deviation, categorical variables as frequency and percentage. Group comparisons were performed using the independent samples t-test, and ROC curve analysis was used to determine cut-off values. Statistical significance was set at p < 0.05.
Results
The study included 180 patients, 156 (86.7%) male and 24 (13.3%) female, with a mean age of 65.9 ± 10.5 years (range 45–90). The mean high-grade component proportion was 33.7% ± 29.8% (median 22.5; range 2–80) (Figure 1). Lamina propria invasion was present in 25% of cases (n = 45). Recurrence occurred in 48 patients (26.7%), while 132 (73.3%) remained recurrence-free. The mean recurrence- free interval was 10.3 ± 5.7 months, and the mean overall survival was 14.6 ± 10.1 months. The two- year survival rate was 73.3% (Table 1).
FIGURE 1
TABLE 1
| Characteristics | n (%)/Median | Min-Max |
|---|---|---|
| Sex | Male | 156 (86.7) |
| | Female | 24 (13.3) |
| Age (years) | 65.9 | 65 (45–90) |
| Recurrence | Absent | 132 (73.3) |
| | Present | 48 (26.7) |
| Lamina propria invasion | Absent | 135 (75.0) |
| | Present | 45 (25.0) |
| High-grade proportion (%) | 33.7 | 22.5 (2–80) |
| Recurrence-free interval (months) | 10.3 | 9.5 (3–19) |
| Survival time (months) | 14.6 | 15 (1–32) |
Demographic, clinical, and pathological characteristics of patients with urothelial carcinoma.
Survival-based analysis revealed significant differences: patients who survived <2 years had a higher mean proportion of high-grade component (46.4% vs. 29.1%,p = 0.045) and were older (72.6 vs. 63.4 years, p = 0.002), although recurrence-free interval did not differ between these survival groups. Recurrence status, on the other hand, was not associated with significant differences in high-grade proportion, age, or survival time (p > 0.05) (Table 2).
TABLE 2
| Comparison | Group 1 | Group 2 | p-value |
|---|---|---|---|
| Recurrence | Recurrence | No recurrence | |
| High-grade proportion (%) | 37.6 ± 31.6 | 32.3 ± 29.4 | 0.549 |
| Age (years) | 63.3 ± 9.9 | 66.8 ± 10.6 | 0.254 |
| Survival (months) | 15.8 ± 7.7 | 14.1 ± 11.3 | 0.765 |
| 2-year survival | <2 years | ≥2 years | |
| High-grade proportion (%) | 46.4 ± 28.4 | 29.1 ± 29.2 | 0.045 |
| Age (years) | 72.6 ± 10.4 | 63.4 ± 9.5 | 0.002 |
| Recurrence-free time (months) | 9.2 ± 5.4 | 10.7 ± 6.0 | 0.634 |
| Lamina propria invasion | Invasion | No invasion | |
| High-grade proportion (%) | 51.3 ± 31.5 | 27.8 ± 27.1 | 0.007 |
| Age (years) | 74.1 ± 11.7 | 63.1 ± 8.5 | <0.001 |
| Recurrence-free time (months) | 12.0 ± 6.2 | 9.9 ± 5.7 | 0.572 |
| Survival (months) | 15.9 ± 10.6 | 13.7 ± 10.2 | 0.681 |
Comparison of demographic and clinicopathological characteristics according to recurrence status, 2-year survival, and lamina propria invasion.
Group 1 and Group 2 represent the categories defined separately for each comparison: recurrence vs. no recurrence, <2 years vs. ≥2 years survival, and lamina propria invasion vs. no invasion.
Lamina propria invasion was associated with a significantly higher high-grade proportion (51.3% vs. 27.8%, p = 0.007) and older age (74.1 vs. 63.1 years, p < 0.001), while recurrence-free interval and overall survival did not differ significantly between groups (Table 2).
ROC curve analysis demonstrated that a high-grade component ≥27.5% (AUC = 0.682, p = 0.032) and age ≥66.5 years (AUC = 0.756, p = 0.003) were significant predictors of shorter survival. In contrast, no significant cut-off values were identified for recurrence with respect to high-grade proportion, age, or survival time (p > 0.05). Recurrence-free interval was also not a significant predictor (p > 0.05). Kaplan–Meier survival analysis similarly showed a trend toward worse survival in patients with >27.5% high-grade component, although this was not statistically significant (log-rank p = 0.061) (Figure 2).
FIGURE 2
Discussion
According to the most recent 2022 WHO classification of tumors of the urinary system and male genital organs, grade heterogeneity is observed in approximately one-third of UC []. It has generated considerable debate, particularly regarding the grading of low-grade UC that contain a limited proportion of high-grade component. One of the main reasons why the two-tier (WHO 2004) and three-tier (WHO 1973) systems continue to be compared is precisely this diagnostic challenge [].
It has been reported that, when the 2004 and 1973 grading systems were compared, UC classified as grade 3 in the 1973 system showed higher rates of progression compared with tumors categorized as high-grade in the two-tier system. This difference was attributed to the inclusion of tumors with only focal high-grade components in the high-grade category under the 2004 system. It was further emphasized in the same study that the 2004 classification may result in lower reproducibility when applied to such heterogeneous tumors. It was also noted that, in some cases, degenerative changes mimicking high-grade features may further contribute to misclassification [].
Similarly, in a multicenter study, it was shown that the 1973 classification correlated more strongly with tumor progression than the 2004 system in non–muscle-invasive bladder carcinomas (Ta/T1), although no difference was observed in recurrence rates between the two systems []. These observations suggest that the high-grade category in current classification represents a heterogeneous group of tumors, raising concerns that a subset of patients may receive unnecessary treatment. Determining a minimum proportion of high-grade component necessary for classification as high-grade therefore carries critical clinical importance [].
It has been reported that tumors with grade heterogeneity tend to exhibit clinical behavior similar to low-grade tumors []. In another study, the response of such tumors to intravesical BCG therapy was analyzed, and higher response rates were observed compared with pure high-grade tumors, leading to the conclusion that they may represent a ‘favorable prognostic subtype’ []. On the other hand, it is also reported that non–muscle-invasive papillary UC with grade heterogeneity exhibited outcomes more similar to low-grade tumors, although the difference was not statistically significant [].
The 2023 ISUP consensus report emphasized that current data support an intermediate behavior of low- grade UC with focal high-grade areas. However, consensus has not yet been reached on the exact proportion that defines “focal high-grade” 13. In a 2022 review, it was noted that multidisciplinary studies, along with emerging artificial intelligence systems, may provide clearer insights into the behavior of this group of tumors 7. The 2022 WHO classification suggests using a ≥5% threshold for designating tumors as high-grade, while at the same time emphasizing the need for further evidence []. In support of this approach, 160 papillary UC with grade heterogeneity were recently evaluated, and it was reported that when a 5% threshold was applied, tumors classified as high-grade demonstrated better survival compared with pure high-grade tumors but worse survival compared with pure low-grade tumors [, ].
In the 2021 update of the European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer, it was emphasized that risk stratification should be applied when determining treatment procedures for this group of tumors, underscoring the importance of tumor size, multiplicity, and the presence of carcinoma in situ (CIS) [].
In our study we did not demonstrate any significant corelation between high-grade proportion and recurrence. Notably, a negative correlation was observed between high-grade proportion and overall survival, and a similar negative correlation was also present between high-grade proportion and survival time.
A statistically significant association was found between lamina propria invasion and the proportion of high-grade component (p = 0.007). This finding is consistent with the expected invasive potential of high-grade tumors.
When overall survival was considered, a threshold of 27.5% for the high-grade component was calculated in our study. This threshold suggests that tumors with a high-grade component exceeding 27.5% behave more similarly to pure high-grade tumors. Kaplan–Meier survival analysis demonstrated a parallel trend, with patients harboring >27.5% high-grade component experiencing worse survival, although this did not reach statistical significance. The value identified is higher than the 5% cut-off proposed by the 2022 WHO classification; however, the need for further studies is evident. Nonetheless, in routine pathological practice, applying a higher cut-off for the high-grade component may help limit subjectivity caused by focal degenerative changes and may improve reproducibility.
Our primary aim was to evaluate the prognostic impact of the high-grade proportion and to investigate a potential threshold value; therefore, cases with tumor multifocality or coexisting CIS were not included among the 180 analyzed. In addition, the absence of tumor size data, which represents an important factor in risk stratification, can be considered a limitation of our study.
In conclusion, our findings demonstrate a strong association between the proportion of high-grade component and survival in non–muscle-invasive UC. Moreover, our study provides evidence suggesting that a threshold higher than 5% may be more appropriate when assigning tumors to the high-grade category. However, to strengthen consistency in grading and ensure appropriate treatment decisions, multicenter studies incorporating tumor size and other clinical and prognostic parameters are needed.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The study had been reviewed and approved by the Ankara Etlik City Hospital Clinical Research Ethical Committee (the approval number: 125/08, the date of the approval: 29.11.2021). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
GA; Methodology: GA and KD; Investigation: GA, KD, MT, and EÖ; Histopathological evaluation: GA, MT, and EÖ; Figure and table preparation: MT and KD; Writing—original draft: GA; Writing—review and editing: GA, KD, MT, and EÖ. All authors contributed to the article and approved the submitted version.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
References
1.
WHO Classification of Tumours Editorial Board. In: Urinary and Male Genital Tumours. 5th ed., 8. Lyon (France): International Agency for Research on Cancer (2022).
2.
SobinLH. The WHO histological classification of urinary bladder tumours. Urol Res (1978) 6(4):193–5. 10.1007/BF00262616
3.
van der KwastTLiedbergFBlackPCKamatAvan RhijnBWGAlgabaFet alInternational society of urological pathology expert opinion on grading of urothelial carcinoma. Eur Urol Focus (2022) 8(2):438–46. 10.1016/j.euf.2021.03.017
4.
BeijertIJChengLLiedbergFPlassKWilliamsonSRGonteroPet alInternational opinions on grading of urothelial carcinoma: a survey among european association of urology and international society of urological pathology members. Eur Urol Open Sci (2023) 52:154–65. 10.1016/j.euros.2023.03.019
5.
VarmaMCompératEvan der KwastT. Head-to-head: how many categories for grading urothelial carcinoma?Histopathology (2024) 84(3):421–8. 10.1111/his.15091
6.
GofritONPizovGShapiroADuvdevaniMYutkinVLandauEHet alMixed high and low grade bladder tumors—are they clinically high or low grade?J Urol (2014) 191(6):1693–6. 10.1016/j.juro.2013.11.056
7.
RaspolliniMRComperatEMLopez-BeltranAMontironiRCimadamoreATsuzukiTet alNews in the classification of WHO 2022 bladder tumors. Pathologica (2022) 115(1):32–40. 10.32074/1591-951X-838
8.
KrügerSThornsCBöhleAFellerAC. Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol (2003) 35(2):169–73. 10.1023/b:urol.0000020305.70637.c6
9.
MiWZangCZhaoJKamatAMWeiPHanselDEet alMixed-grade papillary urothelial carcinoma with a minor high-grade component shows a significantly worse clinical outcome than low-grade papillary urothelial carcinoma. Hum Pathol (2025) 163:105904. 10.1016/j.humpath.2025.105904
10.
LonatiCSoriaFPradereBD'AndreaDLaukhtinaEMertensLSet alComment on: “accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG”. Minerva Urol Nephrol (2023) 75(3):407–9. 10.23736/S2724-6051.23.05337-5
11.
HoPMoranGWWangVLiGVirkRKMcKiernanJMet alThe effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer. Urol Oncol (2022) 40(2):60.e11–60.e16. 10.1016/j.urolonc.2021.07.003
12.
AminMBTickooSK. Diagnostic Pathology: Genitourinary. 3rd ed. Elsevier (2022).
13.
PanerGPKamatANettoGJSamaratungaHVarmaMBubendorfLet alInternational society of urological pathology (ISUP) consensus conference on current issues in bladder cancer. Working group 2: grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and Non-Ur. Am J Surg Pathol (2024) 48(1):e11–e23. 10.1097/PAS.0000000000002077
14.
SoukupVČapounOCohenDHernándezVBabjukMBurgerMet alPrognostic performance and reproducibility of the 1973 and 2004/2016 world health organization grading classification systems in Non-muscle- invasive bladder cancer: a european association of urology non-Muscle invasive bladder cancer guidelines panel sys. Eur Urol (2017) 72(5):801–13. 10.1016/j.eururo.2017.04.015
15.
van RhijnBWGHentschelAEBründlJCompératEMHernándezVČapounOet alPrognostic value of the WHO1973 and WHO2004/2016 classification systems for grade in primary Ta/T1 non-muscle-invasive bladder cancer: a multicenter european association of urology non-Muscle-invasive bladder cancer guidelines panel study. Eur Urol Oncol (2021) 4(2):182–91. 10.1016/j.euo.2020.12.002
16.
ChangSSBoorjianSAChouRClarkPEDaneshmandSKonetyBRet alDiagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol (2016) 196(4):1021–9. 10.1016/j.juro.2016.06.049
17.
SchubertTDanzigMRKotamartiSGhandourRALascanoDDubowBPet alMixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome. World J Urol (2015) 33(6):847–52. 10.1007/s00345-014-1383-5
18.
ReisLOTaheriDChauxAGunerGMendoza RodriguezMABivalacquaTJet alSignificance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Hum Pathol (2016) 47(1):20–5. 10.1016/j.humpath.2015.09.007
19.
KirGCecikogluGETopalCSSorkunMHCulpanMSucekenFYet alClinicopathologic features and prognostic significance of mixed (low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma. Virchows Arch (2023) 483(5):621–34. 10.1007/s00428-023-03625-3
20.
KhalatbariFMoafi-MadaniMAminA. Mixed-grade urothelial carcinoma: insights into clinical behavior and prognostic implications compared to pure low-grade and high-grade urothelial carcinomas. Arch Pathol Lab Med (2024) 148(12):1352–7. 10.5858/arpa.2023-0367-OA
21.
SylvesterRJRodríguezOHernándezVTurturicaDBauerováLBruinsHMet alEuropean association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol (2021) 79(4):480–8. 10.1016/j.eururo.2020.12.033
Summary
Keywords
bladder cancer, grading, heterogeneity, invasion, uro-oncology
Citation
Alkan GV, Doğan K, Türk Alkan M and Önder E (2026) Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity. Pathol. Oncol. Res. 32:1612553. doi: 10.3389/pore.2026.1612553
Received
15 July 2026
Revised
16 September 2026
Accepted
21 September 2026
Published
05 October 2026
Volume
32 - 2026
Edited by
Tibor Szarvas, Semmelweis University, Hungary
Updates
Copyright
© 2026 Alkan, Doğan, Türk Alkan and Önder.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gökhan Veli Alkan, g_veli_alkan@hotmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.